Wird geladen...
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives...
Gespeichert in:
| Veröffentlicht in: | Blood Adv |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6988397/ https://ncbi.nlm.nih.gov/pubmed/31985808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001158 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|